Logo

SLP

Simulations Plus, Inc.

SLP

Simulations Plus, Inc. • NASDAQ
$17.00 ▼ -1.68% (-0.29)
Market Cap $342.16 M
52w High $37.67
52w Low $12.39
Dividend Yield 0.24%
P/E -5.4
Volume 123.99K
Outstanding Shares 20.13M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $20.363M ▼ $87.258M ▲ $-67.317M ▼ -330.585% ▼ $-3.35 ▼ $5.313M ▲
Q2-2025 $22.432M ▲ $10.415M ▲ $3.074M ▲ 13.704% ▲ $0.15 ▲ $4.986M ▲
Q1-2025 $18.924M ▲ $10.092M ▲ $206K ▼ 1.089% ▼ $0.01 ▼ $2.391M ▲
Q4-2024 $18.664M ▲ $7.976M ▼ $843K ▼ 4.517% ▼ $0.042 ▼ $1.055M ▼
Q3-2024 $18.544M $11.377M $3.137M 16.917% $0.16 $3.143M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $28.45M ▲ $134.36M ▼ $10.581M ▼ $123.779M ▼
Q2-2025 $21.385M ▲ $201.427M ▲ $11.879M ▼ $189.548M ▲
Q1-2025 $18.17M ▼ $196.916M ▲ $12.221M ▼ $184.695M ▲
Q4-2024 $20.255M ▼ $196.639M ▲ $14.208M ▲ $182.431M ▲
Q3-2024 $118.967M $192.691M $11.832M $180.859M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-67.317M ▼ $8.144M ▲ $7.807M ▲ $7K ▲ $15.958M ▲ $7.847M ▲
Q2-2025 $3.074M ▲ $5.669M ▲ $684K ▲ $-1.548M ▼ $4.805M ▲ $5.603M ▲
Q1-2025 $206K ▼ $-1.274M ▼ $-3.138M ▲ $288K ▲ $-4.124M ▲ $-1.36M ▼
Q4-2024 $843K ▼ $1.664M ▼ $-99.5M ▼ $-945K ▲ $-98.781M ▼ $941K ▼
Q3-2024 $3.137M $5.684M $69.913M $-3.536M $72.061M $4.725M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
License and Maintenance
License and Maintenance
 $30.00M ▲$10.00M ▼$10.00M ▲$10.00M ▲
Service
Service
 $20.00M ▲$10.00M ▼$10.00M ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has trended upward over the past few years, but the growth is steady rather than explosive. Profitability is solid for a software-heavy business, with healthy gross margins and consistent operating income. Earnings per share have been fairly stable, with a prior peak followed by a slight step back, suggesting that growth investments and acquisition-related costs may be offsetting some of the underlying margin strength. Overall, the income statement shows a profitable, niche software company that is growing, but not at a hyper-growth pace, and is balancing expansion with maintaining solid profits.

Balance Sheet

Balance Sheet The balance sheet looks conservative and resilient. The company carries essentially no financial debt and is funded largely by shareholder equity, which reduces financial risk. Total assets have gradually expanded, reflecting ongoing investment in the business and acquisitions. Cash, however, has come down meaningfully in the most recent period, likely tied to deals and growth initiatives, which makes the company somewhat less cushioned than before but still in a net cash position. Overall, it appears financially sound with room to keep investing, though less cash flexibility than a couple of years ago.

Cash Flow

Cash Flow Cash flow from operations has been consistently positive, which supports the quality of reported earnings. Free cash flow is also positive but has eased off recently, hinting at higher working capital needs or integration costs around acquisitions. Capital spending is modest, reflecting the asset-light, software-driven nature of the business. The pattern suggests a company that reliably converts a good portion of its profits into cash, but where future cash generation will depend on how well it manages growth and integration spending.

Competitive Edge

Competitive Edge Simulations Plus occupies a specialized and defensible niche in drug modeling and simulation, serving pharmaceutical and biotech clients that embed its tools deeply into their R&D and regulatory workflows. Its software is widely accepted by regulators and used in many drug submissions, which builds trust and makes it hard for customers to switch. High switching costs, strong scientific credibility, and a long track record create a meaningful competitive moat. At the same time, the company operates in a dynamic space where larger software players, consulting firms, and new AI-driven entrants could intensify competition, especially if industry budgets tighten.

Innovation and R&D

Innovation and R&D Innovation sits at the center of the company’s strategy. It has steadily expanded from core pharmacokinetic modeling into broader systems pharmacology, toxicology, and now clinical trial training and simulation. The integration of AI, machine learning, and cloud delivery into its platforms is a key next chapter and could enhance both product performance and scalability if executed well. Acquisitions like Pro-ficiency, DILIsym, and Immunetrics extend its reach across the drug development lifecycle, but they also raise execution risks around integration, culture, and realizing promised synergies. The company is well aligned with emerging themes like reduced animal testing and more model-based development, which could support long-term relevance if it keeps its technology at the leading edge.

Summary

Simulations Plus is a profitable, asset-light healthcare software company with a focused niche in drug modeling and simulation. The financial picture shows steady revenue growth, solid margins, a debt-free balance sheet, and generally healthy cash generation, albeit with a recent drawdown in cash and some pressure on free cash flow as it invests and acquires. Competitively, it benefits from deep scientific expertise, regulatory acceptance, and sticky customer relationships that together form a strong moat. Its growth story is tied to continued innovation in AI- and cloud-enabled platforms, effective integration of recent acquisitions, and the pharmaceutical industry’s increasing reliance on in silico methods. Key uncertainties revolve around execution on these initiatives, the pace of industry adoption, and potential competitive responses, but the company appears strategically well positioned within its specialized segment of healthcare technology.

NEWS

November 28, 2025 · 3:10 PM UTC

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Simulations Plus, Inc. (NASDAQ: SLP) and Encourages Investors with Substantial Losses to Contact the Firm

Read more

November 20, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP

Read more

November 10, 2025 · 10:15 PM UTC

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Simulations Plus, Inc. (NASDAQ: SLP) and Encourages Investors with Substantial Losses to Contact the Firm

Read more

November 1, 2025 · 10:53 AM UTC

SIMULATIONS PLUS INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Simulations Plus Investors to Contact the Firm Regarding Their Rights

Read more

October 28, 2025 · 3:30 PM UTC

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

Read more